top of page

Use tab to navigate through the menu items.

PBG BioPharma Inc. announces its lead drug candidate ProZ001 is being used in a groundbreaking phase II, randomized, double-blind, placebo-controlled, cross-over trial

Apr 11, 20242 min read

99

PBG BioPharma Inc. Announces the launch of a Phase 2/3 Clinical Trial on its Cannabinoid-based Drug Product ProZ-001 as an Adjunctive Therapy for Acute Bipolar Depression

Feb 28, 20243 min read

197

Feb 13, 20232 min read

85

Subscribe to our newsletters

Thanks for subscribing!

Work Inquiries

Interested in working with us?

Call Us

Find Out More

Contacts below

Interested in working with us?

Call Us

Social

bottom of page